Clinical trial
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Phase 2 Study of ISIS 678354 Administered Subcutaneously to Patients With Hypertriglyceridemia and Established Cardiovascular Disease (CVD) or at a High Risk for CVD
NCT03385239 is registered in ClinicalTrials.gov with Akcea Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Phase 2 Study of ISIS 678354 Administered Subcutaneously to Patients With Hypertriglyceridemia and Established Cardiovascular Disease (CVD) or at a High Risk for CVD
- Lead sponsor
- Akcea Therapeutics
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- January 30, 2018
- Completion date
- February 25, 2020
- Enrollment
- 114 (actual)
- Sites
- 31
Conditions
As the registry lists them; a condition with its own page is linked.